ctDNA sequencing detects outcomes for pretreated advanced gastrointestinal stromal tumour

Adjuvant endocrine therapy used to treat ER+ HER2- breast cancer

COSMIC-021: Cabozantinib plus atezolizumab gives encouraging clinical activity in inoperable locally advanced/metastatic urothelial carcinoma

Safety follow-up of the randomized, phase 3 study DESTINY-Breast03

Panitumumab plus mFOLFOX6 improves OS for RAS wild-type left sided mCRC

Comment: (RVd) ± , stem cell transplantation and R maintenance shows significance for newly diagnosed myeloma patients

Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer patients

(RVd) ± , stem cell transplantation and R maintenance shows significance for newly diagnosed myeloma patients

High-dose ifosfamide standard of care for recurrent and primary refractory ewing sarcoma

Lenalidomide, bortezomib, and dexamethasone ASCT to progress for NDMM: Phase 3 DETERMINATION trial

Single-agent PD-1 blockade as curative-intent treatment in mismatch repair-deficient locally advanced rectal cancer

N-803-BCG combination shows promising results in BCG-unresponsive NMIBC